GSA Capital Partners’s Mersana Therapeutics MRSN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $140K | Buy |
+18,867
| New | +$140K | 0.01% | 1580 |
|
|
2025
Q1 | – | Sell |
-20,332
| Closed | -$727K | – | 1926 |
|
|
2024
Q4 | $727K | Buy |
20,332
+9,461
| +87% | +$338K | 0.05% | 620 |
|
|
2024
Q3 | $514K | Buy |
10,871
+8,553
| +369% | +$404K | 0.04% | 885 |
|
|
2024
Q2 | $116K | Buy |
2,318
+908
| +64% | +$45.4K | 0.01% | 1519 |
|
|
2024
Q1 | $158K | Buy |
+1,410
| New | +$158K | 0.01% | 1439 |
|
|
2023
Q4 | – | Sell |
-4,072
| Closed | -$129K | – | 1762 |
|
|
2023
Q3 | $129K | Sell |
4,072
-11,432
| -74% | -$362K | 0.01% | 1365 |
|
|
2023
Q2 | $1.28M | Buy |
15,504
+7,325
| +90% | +$602K | 0.13% | 197 |
|
|
2023
Q1 | $840K | Buy |
8,179
+6,889
| +534% | +$708K | 0.08% | 410 |
|
|
2022
Q4 | $189K | Sell |
1,290
-5,390
| -81% | -$790K | 0.02% | 1200 |
|
|
2022
Q3 | $1.13M | Sell |
6,680
-70
| -1% | -$11.8K | 0.15% | 115 |
|
|
2022
Q2 | $780K | Buy |
6,750
+3,602
| +114% | +$416K | 0.12% | 244 |
|
|
2022
Q1 | $314K | Sell |
3,148
-335
| -10% | -$33.4K | 0.04% | 860 |
|
|
2021
Q4 | $542K | Buy |
+3,483
| New | +$542K | 0.07% | 542 |
|
|
2020
Q3 | – | Sell |
-362
| Closed | -$212K | – | 1336 |
|
|
2020
Q2 | $212K | Buy |
+362
| New | +$212K | 0.12% | 317 |
|